Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miglitol - Bayer

Next Previous
Drug Profile

Miglitol - Bayer

Alternative Names: BAY-1099; BAY-M-1099; Diastabol; Glyset; Miglibay; Plumarol; Seibule

Latest Information Update: 29 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Bayer; Lacer; Pfizer; Sanwa Kagaku Kenkyusho
  • Class Alkaloids; Antihyperglycaemics; Imino pyranoses; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Obesity

Most Recent Events

  • 27 Jul 2022 Lacer has been acquired by Italfarmaco
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 03 Dec 2018 Sanwa Kagaku Kenkyusho terminates phase III trial in Type-2 diabetes in Japan (UMIN000025036)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top